Colorectal cancer is the fourth most common type of cancer in the United States.1
One in 24 people will be diagnosed with colorectal cancer in their lifetime.2
The NeoGenomics colorectal cancer solution supports the care continuum with tests that detect genomic alterations relevant to diagnosis, therapy selection, prognosis, and clinical trial options.
Featured colorectal cancer solutions
Neo Comprehensive - Solid Tumor
8-10 Days turnaround time
Comprehensive testing for colorectal cancer patients
Biomarker testing can help providers streamline their approach to treatment decisions, and adherence to guideline-recommended biomarker testing may help improve patient outcomes in general and reduce exposure to expensive therapies that are likely to be ineffective for the patient’s molecular subtype. Next-generation sequencing (NGS) panels have the advantage of being able to detect rare and clinically actionable alterations, as well as targets that may be important in the future (ie, emerging biomarkers) or that are being studied in clinical trials. The NeoGenomics colorectal cancer solution provides the answers you need for therapy selection by utilizing comprehensive genomic profiling (CGP).
Clinically actionable biomarkers for colon cancer3,4
MSI, microsatellite instability.
Add-on testing for therapy selection
Mismatch Repair (MMR) IHC Panel
Global: 2 Days, Image Analysis (Tech-only): 2 Days, Tech-Only (stain only): 1 Day turnaround time
References
National Cancer Institute Surveillance, Epidemiology, and End Results (SEER) Program. Cancer stat facts: colorectal cancer. Accessed December 23, 2024. https://seer.cancer.gov/statfacts/html/colorect.html
Colorectal Cancer Alliance. Colorectal cancer facts and statistics. Accessed December 23, 2024.
https://colorectalcancer.org/basics/facts-and-statisticsSuehnholz SP, Nissan MH, Zhang H, et al. Quantifying the expanding landscape of clinical actionability for patients with cancer. Cancer Discov. 2024;14(1):49-65.
Chakravarty D, Gao J, Phillips S, et al. OncoKB: A precision oncology knowledge base. JCO Precis Oncol. 2017;2017:PO.17.00011.